MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations with two existing programs focused on immune health and precision health, announced that Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”) has commenced the mailing of its management information circular in connection with the upcoming special meeting of their shareholders, which will be held virtually on November 6, 2024.

加利福尼亚州山景城讯（商业新闻短讯）--Aditxt，Inc.（“Aditxt”或“公司”）（纳斯达克：ADTX）是一个创新平台，致力于加速有前景的健康创新，现有两个项目专注于免疫健康和精准健康，宣布Appili Therapeutics Inc.（TSX:APLI；OTCPink:APLIF）（“Appili”）已开始邮寄其管理信息通告，以联系即将于2024年11月6日举行的股东特别会议。

Appili’s board of directors has recommended the shareholders’ vote in favor of the proposed acquisition by Aditxt..

Appili董事会建议股东投票支持ADIXT的拟议收购。

Since its founding in 2015, over CAD $100 million has been raised towards developing antivirals and vaccines for emerging and neglected infectious agents to address a wide range of urgent medical needs in infectious diseases and biodefense. As a result, Appili’s portfolio includes LIKMEZ™, the first and only FDA-approved, taste-masked oral liquid suspension form of the antibiotic, metronidazole.

自2015年成立以来，已经筹集了1亿多加元，用于开发针对新兴和被忽视的传染源的抗病毒药物和疫苗，以满足传染病和生物防御领域的广泛迫切医疗需求。因此，Appili的产品组合包括LIKMEZ™，这是第一个也是唯一一个FDA批准的，掩盖味道的抗生素甲硝唑口服液悬浮形式。

LIKMEZ addresses an unmet need in patients, such as children and the elderly, who have trouble swallowing large pills. LIKMEZ was commercially launched by Saptalis Pharmaceuticals LLC in 2023, and the product is now available to patients and doctors in the United States. Appili has the right to receive sales-based milestone payments and royalties from Saptalis based on sale of the product..

LIKMEZ解决了儿童和老年人等吞咽大药片有困难的患者的未满足需求。LIKMEZ于2023年由Saptalis Pharmaceuticals LLC商业推出，该产品现在可供美国的患者和医生使用。Appili有权根据产品的销售情况从Saptalis获得基于销售的里程碑付款和版税。

In addition, Appili has two programs, ATI-1701 and 1801, which, subject to the renewal of certain legislation, are potentially eligible for FDA Priority Review Vouchers (PRVs). A PRV enables its recipient to expedite the review process for future drug applications upon issuance. While PRVs can be traded, and recent transactions averaged approximately $100 million, their strategic value can potentially extend beyond the secondary market, offering significant advantages in accelerating the development timeline of new treatments..

此外，Appili有两个程序ATI-1701和1801，根据某些立法的更新，它们可能有资格获得FDA优先审查凭证（PRV）。PRV使其接收者能够在发布后加快未来药物申请的审查过程。虽然PRV可以交易，最近的交易平均约为1亿美元，但其战略价值可能会超出二级市场，在加速新疗法的开发时间表方面具有重大优势。

ATI-1701 is a live attenuated vaccine that targets tularemia. This bacterial infection caused by Francisella tularensis is potentially 1,000 times more infectious than anthrax, posing significant threats to public health and national security and, thus, classified as a Category A pathogen by the National Institutes of Health for its potential use in bioterrorism.

ATI-1701是一种针对土拉菌病的减毒活疫苗。这种由土拉弗朗西斯菌引起的细菌感染的传染性可能是炭疽病的1000倍，对公共卫生和国家安全构成重大威胁，因此被美国国立卫生研究院归类为a类病原体，因为它可能用于生物恐怖活动。

ATI-1701 has been awarded a total of $14 million in U.S. Air Force Academy funding commitments, facilitating essential activities like manufacturing, non-clinical studies, and regulatory activities for an Investigational New Drug (IND) application, positioning ATI-1701 as a pivotal element in biodefense strategies.

ATI-1701已获得美国空军学院总计1400万美元的资助承诺，促进了研究性新药（IND）应用的制造、非临床研究和监管活动等基本活动，将ATI-1701定位为生物防御战略的关键要素。

ATI-1801 is another program representing a topical antiparasitic product licensed by the US Army Medical Materiel Development Activity..

ATI-1801是另一个代表美国陆军医疗装备开发活动许可的局部抗寄生虫产品的程序。

ATI-1801 is in advanced clinical trials. This novel topical formulation is being developed to combat cutaneous leishmaniasis (CL), a devastating disease causing disfiguring skin lesions and affecting hundreds of thousands of people annually, primarily in tropical and subtropical regions. Recognized by the World Health Organization as a Neglected Tropical Disease, CL presents significant social and economic challenges, particularly in impoverished communities.

ATI-1801正在进行高级临床试验。目前正在开发这种新型局部制剂来对抗皮肤利什曼病（CL），这是一种破坏性疾病，可导致皮肤损伤，每年影响数十万人，主要是在热带和亚热带地区。CL被世界卫生组织认为是一种被忽视的热带疾病，它带来了重大的社会和经济挑战，特别是在贫困社区。

CL leads to severe physical deformities and social stigma, contributing to isolation and diminished quality of life for those affected. This novel topical formulation of paromomycin provides a more comfortable application of the anti-infective agent to treat CL’s painful and disfiguring lesions effectively..

。这种巴龙霉素的新型局部制剂提供了更舒适的抗感染剂应用，可有效治疗CL的疼痛和毁容病变。

We believe Appili’s team and asset portfolio could address some of the most urgent public health challenges, including antibiotic-resistant infections and bioterrorism threats.”.

我们相信，Appili的团队和资产组合可以解决一些最紧迫的公共卫生挑战，包括抗生素耐药性感染和生物恐怖主义威胁。”

Dr. Don Cilla, President and CEO of Appili Therapeutics, stated, “Appili’s board of directors recommends that shareholders vote in favor of the proposed acquisition by Aditxt, as this transaction aligns with our strategic goals and opens new opportunities across multiple fronts. Appili has received indications of support from approximately 29% of the total voting power.

Appili Therapeutics总裁兼首席执行官Don Cilla博士表示：“Appili董事会建议股东投票支持Aditxt的拟议收购，因为这项交易符合我们的战略目标，并在多个方面开辟了新的机会。Appili已获得约29%总投票权的支持。

By leveraging the Aditxt’s platform, we will significantly enhance our ability to combat life-threatening infectious diseases, enabling us to expand our reach and impact. Our combined expertise will rapidly advance our mission to develop treatments for some of today’s most critical public health challenges.”.

通过利用Aditxt的平台，我们将大大提高我们对抗威胁生命的传染病的能力，使我们能够扩大我们的影响力和影响力。我们的综合专业知识将迅速推进我们的使命，为当今一些最关键的公共卫生挑战开发治疗方法。”

The closing of the transaction with Appili is subject to several conditions, including but not limited to approval of the transaction by Appili’s shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close..

与Appili的交易的结束取决于几个条件，包括但不限于Appili股东对交易的批准，以及ADIXT在结束时筹集足够的资本以资助其义务。无法保证将获得或满足所有成交条件，或交易最终成交。

About Aditxt, Inc.

关于Adittxt，股份有限公司。

Aditxt, Inc.® is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to 'Make Promising Innovations Possible Together.' The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges.

。ADIXT由研究机构、行业合作伙伴和股东组成的生态系统共同推动他们的使命，使有希望的创新成为可能创新平台是ADIXT战略的基石，在该战略中，多学科推动了颠覆性增长，并解决了重大的社会挑战。

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc.

ADIXTT目前运营着两个专注于免疫健康和精准健康的项目。该公司计划推出另外两个专门针对公共卫生和妇女健康的项目。为此，Aditxt已与专注于传染病的Appili Therapeutics，Inc.（以下简称“Appili”）（TSX:APLI；OTCPink:APLIF）签订了安排协议，并与Evofem Biosciences，Inc.签订了合并协议。

(OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.

（OTCQB:EVFM）。每个项目将被设计为自主运作，同时共同推进ADIXT的使命，即发现、开发和部署创新的健康解决方案，以应对一些最紧迫的健康挑战。与Appili和Evofem的每笔交易的结束都要符合几个条件，包括但不限于各自目标股东对交易的批准，以及ADIXT在结束时筹集足够的资本来为其义务提供资金。

No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close..

无法保证将获得或满足所有成交条件，或任何一笔交易最终将成交。

For more information, www.aditxt.com.

有关更多信息，请访问www.aditxt.com。

LinkedIn: https://www.linkedin.com/company/aditxt

LinkedIn: https://www.linkedin.com/company/aditxt

Facebook: https://www.facebook.com/aditxtplatform/

Facebook: https://www.facebook.com/aditxtplatform/

About Appili

关于Appili

Appili is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Appili是一家传染病生物制药公司，旨在建立，投资组合驱动，专注于实现其解决威胁生命的感染的使命。通过系统地识别未满足需求的紧急感染，阿皮利的目标是战略性地开发一系列新疗法，以预防死亡和改善生活。

Appili is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease.

阿皮利目前正在开发多种抗感染药物，包括FDA批准的用于治疗抗菌感染的甲硝唑现成混悬液，用于消除严重生物武器威胁的候选疫苗，以及用于治疗毁容疾病的局部抗寄生虫药。

Led by a proven management team, Appili is at the epicenter of the global fight against infection..

由一支久经考验的管理团队领导，阿皮利正处于全球抗击感染的中心。。

For more information about Appili Therapeutics Inc., visit www.AppiliTherapeutics.com.

有关Appili Therapeutics Inc.的更多信息，请访问www.AppiliTherapeutics.com。

Forward-Looking Statements

前瞻性声明

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company.

本新闻稿中的某些声明构成联邦证券法所指的“前瞻性声明”。前瞻性陈述包括关于公司意图、信念、预测、前景、分析或当前期望的陈述，其中包括公司正在进行和计划中的产品和业务发展；公司融资和执行战略并购计划的能力；公司获得必要资金和合作伙伴开始临床试验的能力；；公司开发商业功能的能力；对产品发布和收入的期望；公司的经营成果、现金需求、支出、财务状况、流动性、前景、增长和战略；公司筹集额外资本的能力；公司经营的行业；以及可能影响行业或公司的趋势。

Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission.

前瞻性陈述并不能保证未来的业绩，由于各种重要因素、市场和其他条件以及ADIXT最新10-K表年度报告中标题为“风险因素”的部分中更充分讨论的风险，以及公司向证券交易委员会提交的其他文件中对潜在风险、不确定性和其他重要因素的讨论，实际结果可能与这些前瞻性陈述所显示的结果存在重大差异。

All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law..

所有此类声明仅在作出之日发表，公司没有义务公开更新或修改任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。